Interstitial Lung Disease Pipeline: Transforming Treatment with 120+ Leading Innovators Paving the Way for the Future of Medicine | DelveInsight

The Interstitial Lung Disease (ILD) landscape is experiencing rapid advancements, fueled by innovative research and transformative breakthroughs. Leading companies like Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, and HEC Pharm, are at the forefront-revolutionizing treatment approaches and unlocking new possibilities in managing ILD. With their cutting-edge therapies, these pioneers are shaping a future where ILD treatments offer hope for improved patient outcomes and long-term impact, providing patients with a better quality of life.

DelveInsight's "Interstitial Lung Disease Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the interstitial lung disease market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging interstitial lung disease drugs, the interstitial lung disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Interstitial Lung Disease Pipeline Report
• DelveInsight's interstitial lung disease pipeline analysis depicts a robust space with 120+ active players working to develop 120+ pipeline drugs for interstitial lung disease treatment.
• The leading interstitial lung disease companies include Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences, and others are evaluating their lead assets to improve the interstitial lung disease treatment landscape.
• Key interstitial lung disease pipeline therapies in various stages of development include RO-0220912, ATYR1923, BI 1015550, Pamrevlumab, Zinpentraxin alfa, LT 0011, Abatacept, PRA023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Ianal, and others.
• In March 2025, Liquidia Corporation (NASDAQ: LQDA) announced that the FDA has accepted its New Drug Application (NDA) resubmission for YUTREPIATM (treprostinil) inhalation powder, intended to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
• In Aug 2024, Liquidia Corporation (NASDAQ: LQDA) announced that the FDA has granted tentative approval for YUTREPIATM (treprostinil) inhalation powder. This treatment is designed for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). While YUTREPIA has met all FDA requirements for safety, quality, and efficacy, final approval is pending the expiration of regulatory exclusivity for a competing product.

Request a sample and discover the recent breakthroughs happening in the interstitial lung disease pipeline landscape @ https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Interstitial Lung Disease Overview
Interstitial lung diseases (ILD), also known as diffuse parenchymal lung diseases, are a diverse group of disorders characterized by lung fibrosis (scarring). These diseases are classified based on histopathological, radiologic, and clinical features.
The classification of ILD categorizes conditions according to clinical, histopathological, or radiologic parameters. Clinically, ILD is grouped by its causes to distinguish between exogenous or endogenous factors. Conditions without a known cause are categorized as idiopathic or primary, relying on histopathological and radiological characteristics for classification. Many forms of ILD have an unknown origin. However, they all share a common developmental process. The histological changes observed result from inflammation in the lung parenchyma-the region of the lung involved in gas exchange, including the alveoli, alveolar ducts, and bronchioles. This area hosts various proteins and pro-fibrotic elements that, after repeated cycles of activation, lead to the accumulation of connective tissue. The fibrosis can be triggered by a known agent deposited in the lung tissue, or in some cases, it develops spontaneously.

Find out more about interstitial lung disease medication @ https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Interstitial Lung Disease Treatment Analysis: Drug Profile
DWN12088: Daewoong Pharmaceutical
DWN12088 is an investigational therapy for idiopathic pulmonary fibrosis (IPF) that has demonstrated promising anti-fibrotic effects and has been found to be safe and well-tolerated in a recently completed Phase I clinical trial involving healthy volunteers. This therapy works by inhibiting the enzyme glutamyl-prolyl-tRNA synthetase, which plays a role in collagen production by preventing proline from being added to the protein sequence. The FDA granted orphan drug designation to DWN12088 for IPF in 2019. The drug is currently in Phase II clinical trials for the treatment of IPF.

LYT-100: PureTech
LYT-100 is PureTech's lead wholly-owned therapeutic candidate. A deuterated version of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being developed for the treatment of inflammatory and fibrotic conditions, including lung diseases such as IPF, other PF-ILDs, and Long COVID respiratory complications, as well as disorders related to lymphatic flow, such as lymphedema. Following a successful Phase 1 study on healthy volunteers, LYT-100 was shown to be well-tolerated at all tested doses. PureTech is advancing LYT-100 through Phase 2 trials, including studies on Long COVID-related respiratory complications and a Phase 2a proof-of-concept study for upper limb secondary lymphedema in breast cancer patients. The company is also progressing with studies for the treatment of IPF and plans to initiate Phase 2 dose-ranging trials for IPF in the first half of 2022.

Key Interstitial Lung Disease Therapies and Companies
• DWN12088: Daewoong Pharmaceutical
• LYT-100: PureTech
• BMS-986278: Bristol-Myers Squibb
• Treprostinil Palmitil: Insmed Incorporated
• INOpulse: Bellerophon Therapeutics

Learn more about the novel and emerging interstitial lung disease pipeline therapies @ https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Interstitial Lung Disease Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous

By Molecule Type
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Interstitial Lung Disease Pipeline Report
• Coverage: Global
• Key Interstitial Lung Disease Companies: Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences, and others.
• Key Interstitial Lung Disease Pipeline Therapies: RO-0220912, ATYR1923, BI 1015550, Pamrevlumab, Zinpentraxin alfa, LT 0011, Abatacept, PRA023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Ianal, and others.

Dive deep into rich insights for drugs used for interstitial lung disease treatment; visit @ https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Interstitial Lung Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Interstitial Lung Disease Pipeline Therapeutics
6. Interstitial Lung Disease Pipeline: Late-Stage Products (Phase III)
7. Interstitial Lung Disease Pipeline: Late-Stage Products (Phase III)
8. Interstitial Lung Disease Pipeline: Mid-Stage Products (Phase II)
9. Interstitial Lung Disease Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.